Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > December 27, 2023
Daily News
December 27, 2023
- Change of Tide in Reform: Lopsided Cost Cuts to Balanced Pro-Innovation Policy
December 27, 2023
- Amylyx Gears Up to Bring New ALS Drug to Japan Market: Country Chief
December 27, 2023
- Regulatory Panel Members Want Clearer Standard for SaMD Efficacy in 2-Stage Approval Scheme
December 27, 2023
- Eisai, Oita University Develop Wearable Sensor to Predict Brain Aβ Buildup
December 27, 2023
- iPSC-Based Parkinson’s Therapy Cleared for Investigator-Led Trial in US: Sumitomo
December 27, 2023
- Health Minister Vows to Beef Up Japan’s Innovation Ecosystem in 2024
December 27, 2023
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…